Tony Hickson BSc, MBA, CLP, RTTP is the Managing Director of Imperial Innovations Ltd (the technology transfer company of Imperial College London). He is also a member of the management committee of IP Group PLC, a £1.5bn listed patient capital investor in university start-ups.
Until Dec 2017 sat on the main PLC board of Touchstone Innovations, a listed balance sheet investor in academic start-ups for 5 years. In his role at Imperial Innovations, Tony is responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Prior to joining the company in 2002, Tony acquired 15 years of commercial and business development experience in bioscience companies including the Wellcome Foundation PLC, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has been a founding board director or observer for a number of start-up companies including Polytherics (now Abzena), Precision Robotics and Catapult Therapy TCR Limited, and was instrumental in the creation of companies such as Thiakis (sold to Wyeth, now Pfizer, in 2008), Respivert (sold to J&J in 2010), Circassia (floated on LSE in 2014), Emcision (sold to Boston Scientific in 2018) and Cell Medica (in advanced clinical studies).
Tony is a Certified Licensing Professional, a board director of PraxisAuril and has chaired the Intellectual Property boards of the European Institute of Technology’s Climate Change KIC and EIT Health. He is also member of the UK government’s BBSRC industry advisory committee and sits on the investment committee of the £40m Apollo Therapeutics investment fund (a JV between 3 Pharma companies and 3 UK universities).